Stability Test of PACAP in Eye Drops.

J Mol Neurosci

Department of Medical Chemistry, Faculty of Medicine, University of Szeged, Dom Sq 8, Szeged, H-6720, Hungary.

Published: August 2021

PACAP is a neuropeptide with widespread distribution and diverse biological functions. It has strong cytoprotective effects mediated mainly through specific PAC1 receptors. Experimental data show protective effects of PACAP in the retina and cornea in several pathological conditions. Although intravitreal injections are a common practice in some ocular diseases, delivery of therapeutic agents in the form of eye drops would be more convenient and would lead to fewer side effects. We have previously shown that PACAP, in the form of eye drops, is able to pass through the ocular barriers and can exert retinoprotective effects. As eye drops represent a promising form of administration of PACAP in ocular diseases, it is important to investigate the stability of PACAP in solutions used in eye drops. In this study, the stability of PACAP1-27 and PACAP1-38 in eye drops was measured in four common media and a commercially available artificial tear solution at both room temperature and +4 °C. Mass spectrometry results show that the highest stability was gained with PACAP1-38 in water and 0.9% saline solution at +4 °C, representing 80-90% drug persistence after 2 weeks. PACAP1-38 in the artificial tear showed very fast degradation at room temperature, but was stable at +4 °C. In summary, PACAP1-38 has higher stability than PACAP1-27, with highest stability at +4 °C in water solution, but both peptides in each medium can be stored for relatively longer periods without significant degradation. These data can provide reference for future therapeutic use of PACAP in eye drops.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349324PMC
http://dx.doi.org/10.1007/s12031-020-01532-9DOI Listing

Publication Analysis

Top Keywords

eye drops
28
pacap eye
8
effects pacap
8
ocular diseases
8
form eye
8
stability pacap1-27
8
artificial tear
8
room temperature
8
highest stability
8
pacap
7

Similar Publications

Prcis: Preservative-free omidenepag isopropyl (OMDI) 0.002% ophthalmic solution and OMDI 0.002% ophthalmic solution preserved with benzalkonium chloride were bioequivalent in lowering intraocular pressure after 4 weeks' treatment in patients with primary open-angle glaucoma or ocular hypertension.

View Article and Find Full Text PDF
Article Synopsis
  • A 17-month-old child's scheduled surgery for plagiocephaly was postponed due to a past allergic reaction to atropine-based eye drops, prompting an allergy assessment.
  • Skin tests confirmed an allergy to atropine, which is uncommon in pediatric anesthesia cases, highlighting the importance of thorough preoperative consultations.
  • This case exemplifies the necessity of listening to parental concerns and the benefits of careful allergy testing to ensure a safe surgical experience.
View Article and Find Full Text PDF

Systemic administration of Janus kinase (JAK) inhibitors is effective in treating chronic graft-versus-host disease (cGVHD) but is associated with side effects. Topical drug administration effectively minimizes side effects. We aimed to investigate potential trends of the efficacy of topical delgocitinib administration in a mouse model.

View Article and Find Full Text PDF

[Peripheral ulcerative keratitis associated with dupilumab: a case report].

Zhonghua Yan Ke Za Zhi

January 2025

Department of Ophthalmology,Beijing Hospital, National Center of Gerontology Institute of Geriatric Medicine,Chinese Academy of Medical Sciences,Beijing100730,China.

Article Synopsis
  • A 68-year-old male experienced irritation in both eyes, including symptoms like photophobia and tearing, after starting dupilumab for severe atopic dermatitis.
  • He had a specific corneal ulcer in the right eye and a pannus in the left eye, but tests ruled out infections.
  • Treatment with eye drops led to significant improvement, and follow-up revealed healing of the corneal lesions and improved vision.
View Article and Find Full Text PDF

Systemic adverse drug events to topical prostaglandin analogs for treating glaucoma: a retrospective focused pharmacovigilance study.

BMC Ophthalmol

December 2024

Department of Pharmacology & Therapeutics, College of Medicine & Health Sciences, Arabian Gulf University, Manama, Kingdom of Bahrain.

Background: Prostaglandin analogs are first-line treatments for open-angle glaucoma due to their proven efficacy in reducing intraocular pressure. Despite their topical administration, systemic adverse drug Events (ADEs) have been reported. This study investigates the systemic ADEs associated with topical prostaglandin analogs using the United States Food and Drug Administration (USFDA) Adverse Drug Event Reporting System (AERS) database.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!